# US 2026/0202403 A1 · Methods of diagnosing and treating neuropsychiatric diseases and disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0202403 A1
- Document ID: US20260202403A1
- Status: Published application
- Kind: A1
- Application number: 19/134,653
- Filed: 2023-11-30
- Published: 2026-07-16
- Earliest claimed: 2022-12-01
- Applicants: Yale University
- Inventors: Christopher Pittenger; Jian Xu; Aaron Ring
- Web page: https://patentgrep.com/patent/US20260202403A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 16/2887: {against CD20}
- G01N 2333/49: Platelet-derived growth factor [PDGF]
- G01N 2333/521: Chemokines
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N 2800/30: Psychoses; Psychiatry
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are methods of diagnosing neuropsychiatric diseases and disorders by means of identifying antigens that bind to specific cells in whole neural tissue. In a non-limiting example, a method of diagnosing pediatric acute-onset neuropsychiatric syndrome (PANS) is provided.

## Claims

### Claim 1

A method for diagnosing a neuropsychiatric disease or disorder in a human subject, the method comprising:
i) obtaining a serum sample comprising IgG from the human subject;
ii) quantifying using ELISA an amount of an autoantibody binding to the target antigen set in the serum sample, so as to provide an ELISA value, wherein the autoantibody comprises at least one of an anti-LRP11 antibody, an anti-CXCL3 antibody, an anti-PDGFB antibody, and an anti-CSPG5 antibody; and
iii) diagnosing the human subject with PANS if the ELISA value is greater than or equal to 3 standard deviations above a control mean ELISA value.

### Claim 2 (depends on 1)

The method of claim 1, wherein the neuropsychiatric disease or disorder is acute-onset neuropsychiatric syndrome (PANS) or pediatric autoimmune disorder associated with Streptococcus (PANDAS).

### Claim 3 (depends on 1)

The method of claim 1, wherein the target antigen is LRP11.

### Claim 4 (depends on 1)

The method of claim 1, wherein the target antigen is CXCL3.

### Claim 5 (depends on 1)

The method of claim 1, wherein the target antigen is CSPG5.

### Claim 6 (depends on 1)

The method of claim 1, wherein the target antigen is PDGFB.

### Claim 7 (depends on 1)

The method of claim 1, wherein the autoantibody is an anti-LRP11 antibody.

### Claim 8 (depends on 1)

The method of claim 1, wherein the autoantibody is an anti-CXCL3 antibody.

### Claim 9 (depends on 1)

The method of claim 1, wherein the autoantibody is an anti-CSPG5 antibody.

### Claim 10 (depends on 1)

The method of claim 1, wherein the autoantibody is an anti-PDGFB antibody.

### Claim 11 (depends on 1)

The method of claim 1, further comprising treating the human subject to reduce or ameliorate at least one symptom of the neuropsychiatric disease or disorder.

### Claim 12 (depends on 12)

The method of claim 12, wherein the treating comprises administering to the human subject a therapeutically effective amount of at least one of IVIG, rituximab, a steroid, and a non-steroidal anti-inflammatory drug (NSAID).

### Claim 13

A method for identifying a disease-inducing agent in a neuropsychiatric disease or disorder, the method comprising:
i) providing an isolated tissue sample containing cholinergic interneurons (CINs);
ii) identifying one or more antibodies in a serum specimen that bind to the CINs:
iii) quantifying using ELISA an amount of the one or more antibodies that bind to the CINs so as to provide an ELISA value; and
iv) comparing the ELISA value against a control ELISA value to determine whether the one or more antibodies are disease-inducing agents.

### Claim 14 (depends on 13)

The method of claim 13, wherein the isolated tissue sample is a mammalian tissue.

### Claim 15 (depends on 13)

The method of claim 13, wherein the neuropsychiatric disease or disorder is PANS.

### Claim 16 (depends on 13)

The method of claim 13, wherein the neuropsychiatric disease or disorder is PANDAS.

### Claim 17 (depends on 13)

The method of claim 13, further comprising treating a human subject to reduce or ameliorate at least one symptom of the neuropsychiatric disease or disorder if the one or more antibodies are disease-inducing agents.

### Claim 18 (depends on 17)

The method of claim 17, wherein the treating comprises administering to the human subject a therapeutically effective amount of at least one of IVIG, rituximab, a steroid, and a non-steroidal anti-inflammatory drug (NSAID).
